DelveInsight’s “Malignant Pleural Effusion Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Malignant Pleural Effusion market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Malignant Pleural Effusion drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Malignant Pleural Effusion treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Malignant Pleural Effusion: An Overview
A Malignant Pleural Effusion (MPE) is the build-up of fluid and cancer cells that collects between the chest wall and the lung. This can cause shortness of breath and/or chest discomfort. It is a fairly common complication in several different cancers. It forms when cells from either lung cancer or another type of cancer spread to the pleural space. These cancer cells increase the production of pleural fluid and cause decreased absorption of the fluid.
People with lung, breast, and lymphoma (a cancer of lymphatic tissue) are most likely to get an MPE. Mesothelioma (a rare pleura cancer) is another common cause of MPE. Other causes of MPE include cancer that has spread from the stomach, kidney, ovaries, colon, etc.
Malignant Pleural Effusion Market Key Facts
-
The total market size of Malignant Pleural Effusion in the United States accounted for about USD 1,714 million in 2021.
-
In EU5, the total market size of Malignant Pleural Effusion was about USD 1,772 million in 2021.
-
In Japan, the total market size of Malignant Pleural Effusion was about USD 1,076 million in 2021.
-
In 2021, the total diagnosed incident cases of Malignant Pleural Effusion were about 480 thousand in the 7MM.
-
The highest number of incident cases of Malignant Pleural Effusion was observed in the United States, which solely accounted for approximately 241 K of the total incident cases in 2021.
-
Among the European countries, Germany had the highest diagnosed population of Malignant Pleural Effusion with around 49 K cases, followed by UK and France with approximately 37K and 38.8K cases in 2021. Although all over the EU5 market, the total diagnosed of the disease was around 186 K cases.
Malignant Pleural Effusion Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Malignant Pleural Effusion pipeline therapies. It also thoroughly assesses the Malignant Pleural Effusion market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Malignant Pleural Effusion drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Malignant Pleural Effusion Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Malignant Pleural Effusion epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Malignant Pleural Effusion epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Malignant Pleural Effusion Epidemiology, Segmented as –
-
Total Incident Cases of Pleural Effusion (PE) in the 7MM [2019–2032]
-
Total Incident Cases of MPE by Tumor Type in the 7MM [2019–2032]
-
Total Incident Cases of MPE in the 7MM [2019–2032]
-
Total Diagnosed Cases of MPE in the 7MM [2019–2032]
-
Total Treated Cases of MPE in the 7MM [2019–2032]
Malignant Pleural Effusion Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Malignant Pleural Effusion market or expected to be launched during the study period. The analysis covers the Malignant Pleural Effusion market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Malignant Pleural Effusion drugs based on their sale and market share.
The report also covers the Malignant Pleural Effusion pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Malignant Pleural Effusion companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Malignant Pleural Effusion Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/malignant-pleural-effusion-market
Malignant Pleural Effusion Therapeutics Analysis
Several major pharma and biotech companies developing therapies for Malignant Pleural Effusion. Currently, RS Oncology is leading the therapeutics market with its Malignant Pleural Effusion drug candidates in the most advanced stage of clinical development.
Malignant Pleural Effusion Companies Actively Working in the Therapeutics Market Include
-
LIPAC Oncology
-
RS Oncology
-
Clover Biopharmaceuticals
-
Gongwin Biopharm Holdings
-
Simcere Pharmaceutical Group
-
RS Oncology
-
Genelux Corporation
-
Candel Therapeutics
And Many Others
Emerging and Marketed Malignant Pleural Effusion Therapies Covered in the Report Include:
-
LEITP-1009: LIPAC Oncology
-
RSO-021: RS Oncology
-
SCB-313: Clover Biopharmaceuticals
-
GL-ONC1: Genelux Corporation
-
CAN-2409: Candel Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/malignant-pleural-effusion-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Malignant Pleural Effusion Competitive Intelligence Analysis
4. Malignant Pleural Effusion Market Overview at a Glance
5. Malignant Pleural Effusion Disease Background and Overview
6. Malignant Pleural Effusion Patient Journey
7. Malignant Pleural Effusion Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Malignant Pleural Effusion Treatment Algorithm, Current Treatment, and Medical Practices
9. Malignant Pleural Effusion Unmet Needs
10. Key Endpoints of Malignant Pleural Effusion Treatment
11. Malignant Pleural Effusion Marketed Therapies
12. Malignant Pleural Effusion Emerging Drugs and Latest Therapeutic Advances
13. Malignant Pleural Effusion Seven Major Market Analysis
14. Attribute Analysis
15. Malignant Pleural Effusion Market Outlook (In US, EU5, and Japan)
16. Malignant Pleural Effusion Companies Active in the Market
17. Malignant Pleural Effusion Access and Reimbursement Overview
18. KOL Views on the Malignant Pleural Effusion Market
19. Malignant Pleural Effusion Market Drivers
20. Malignant Pleural Effusion Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/malignant-pleural-effusion-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Gestational Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Gestational Diabetes market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Gestational Diabetes market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/